Physician profile
Tun Jie
NPI 1730308123
$14,915.25
in general payments reported to CMS, 2019-2025
20 companies · $9,750 in 2025
The $9,750 reported for 2025 was more than what 91% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $3,153 · 2021: $194 · 2022: $124 · 2023: $246 · 2024: $851 · 2025: $9,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,900 · Travel and Lodging: $2,078 · Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,900.00 |
| Travel and Lodging | $2,077.84 |
| Food and Beverage | $1,870.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $7,084.17 | 2025 | |
| Intuitive Surgical, INC. | $3,323.58 | 2019-2020 | |
| Medical Device Business Services, INC. | $2,310.37 | 2024-2025 | Echelon Flex |
| Ethicon US, LLC | $321.42 | 2025 | Echelon Circular |
| Astellas Pharma US INC | $228.93 | 2024-2025 | Vyloy |
| Astrazeneca Pharmaceuticals Lp | $202.57 | 2023-2024 | Imfinzi |
| Ipsen Biopharmaceuticals, INC | $191.87 | 2021-2024 | Onivyde |
| Integra Lifesciences Corporation | $174.58 | 2020-2023 | Codman Hakim, Cusa Clarity, Codman Certas |
| Olympus Winter & Ibe Gmbh | $168.30 | 2019 | |
| Medtronic, INC. | $165.51 | 2025 | Eea |
| Agios Pharmaceuticals, INC. | $126.97 | 2024 | Pyrukynd |
| Daiichi Sankyo INC. | $124.49 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $122.64 | 2019-2025 | Envarsus |
| Helsinn Therapeutics (U.S.), INC. | $104.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.67 | 2023-2025 | Livtencity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $63.10 | 2025 | Rybrevant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.52 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $23.41 | 2025 | Exparel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tun Jie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.